Research use only. The materials discussed on this page are sold exclusively for in vitro laboratory research. They are not for human or veterinary use, and nothing here is medical advice or a claim of benefit. Animal-model and clinical data are mentioned only as cited published literature.
Retatrutide and Semaglutide represent two generations of peptides studied in metabolic research. Semaglutide (Ozempic, Wegovy) is a GLP-1 mono-agonist, while Retatrutide is a next-generation triple agonist simultaneously targeting GLP-1, GIP, and glucagon. This comparison synthesizes preclinical data for in vitro research and animal models.
The two compounds
- Retatrutide — view the Retatrutide research product page
- Semaglutide — view the Semaglutide research product page
Comparison table
| Property | Retatrutide | Semaglutide |
|---|---|---|
| Class | GLP-1 / GIP / Glucagon triple agonist | GLP-1 mono-agonist |
| Target receptors | GLP-1R, GIPR, GCGR | GLP-1R only |
| Half-life | ~6 days | ~7 days |
| Origin | Eli Lilly — next-gen metabolic research | Novo Nordisk — modified GLP-1 analog |
| Clinical approval | Phase 3 (trials ongoing) — not approved | FDA/EMA approved for T2 diabetes and obesity (Wegovy) |
| Adiposity mechanism (preclinical) | Energy expenditure ↑ via GCGR + GLP-1/GIP satiety | Central satiety via hypothalamic GLP-1R |
| Typical research model | Diet-induced obesity models, metabolic syndrome | T2 diabetes models, NASH |
| Commercial form | Lyophilized | Lyophilized or ready solution |
| Purity documentation | Batch CoA (HPLC) | Research use only; see product listing |
Research contexts
Literature contexts for Retatrutide
Preclinical diet-induced obesity models, adipose tissue biology, and research on multi-receptor (triple) hormonal modulation.
Literature contexts for Semaglutide
Studies on central satiety, preclinical type 2 diabetes, NASH (non-alcoholic steatohepatitis), research on gastric emptying slowdown.
Mechanisms of action
Retatrutide
Retatrutide simultaneously activates three receptors: GLP-1R (satiety, insulin secretion), GIPR (incretin), and GCGR (glucagon receptor, increases energy expenditure and hepatic lipolysis). Published phase 2 clinical literature (Jastreboff et al., 2023) is listed in the references; this page does not evaluate clinical outcomes.
Semaglutide
Semaglutide selectively binds to GLP-1R, slows gastric emptying, increases glucose-dependent insulin secretion, and activates hypothalamic POMC neurons to induce satiety. Its modified structure (Aib at position 8, C18 lipid chain) confers DPP-IV resistance and albumin binding.
Combined research context
In 2024-2026 metabolic research, Retatrutide is studied as the next generation post-Semaglutide/Tirzepatide. Its triple agonism is the subject of intense preclinical research, particularly on GCGR-mediated energy expenditure.
Related research products
Axion Research Peptides supplies research-grade peptides for in vitro use, with a batch certificate of analysis. Browse Retatrutide, Semaglutide or the full research catalog.
Frequently asked questions
How does the receptor profile of Retatrutide differ from Semaglutide in preclinical studies?
Retatrutide also activates GCGR (the glucagon receptor), which preclinical literature associates with energy expenditure and hepatic lipid handling, in addition to GLP-1/GIP signaling. This page makes no efficacy comparison; published clinical literature is cited in the references.
Is Retatrutide commercially available?
No — Retatrutide is in Phase 3 clinical trials (Eli Lilly). It is not approved by the FDA, EMA, or MHRA. Available only for in vitro scientific research.
What’s the difference vs Tirzepatide?
Tirzepatide (Mounjaro) is a GLP-1/GIP dual agonist. Retatrutide adds GCGR (glucagon) activity, a third receptor target that is studied in preclinical metabolic models.
Comparable half-life?
Reported half-lives are similar (about 6-7 days), consistent with long-acting pharmacokinetic profiles.
Are these peptides approved in the USA for research?
Retatrutide is intended exclusively for in vitro research (not clinical approved). Semaglutide is an FDA-approved clinical product; research-grade material listed by Axion Research Peptides is for in vitro research use only.
Scientific references
- Jastreboff AM et al., 2023 — Retatrutide phase 2, NEJM.
- Wilding JPH et al., 2021 — Semaglutide STEP trials, NEJM.
Regulatory disclaimer
The peptides discussed in this comparison are not approved by the FDA, EMA, MHRA, or any regulatory agency for human or veterinary clinical use, except where a specific approved product is named (for example, tesamorelin as Egrifta). They are sold by Axion Research Peptides exclusively for in vitro scientific research. This page summarizes published literature and is neither medical advice nor a recommendation for clinical use.
